Literature DB >> 12634479

Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study.

Robert A Bermel1, Martins D Innus, Christopher W Tjoa, Rohit Bakshi.   

Abstract

Deep gray matter damage may be an important component of the multiple sclerosis (MS) disease process. We tested whether caudate atrophy occurs in MS, and whether it correlates with conventional MRI or clinical markers of disease progression. Caudate nuclei of 24 MS patients and 10 age-matched healthy controls were traced, normalized, reconstructed and visualized from MRI scans. Normalized bicaudate volume was 19% lower in MS controls ( p< 0.001), an effect that persisted after adjusting for whole-brain atrophy ( p< 0.008). Caudate volume did not correlate with disease duration, physical disability score, whole-brain atrophy, or total T2 hyperintense or T1 hypointense lesion load (all p > 0.05). We conclude that selective caudate atrophy is associated with MS and may occur through direct mechanisms.

Entities:  

Mesh:

Year:  2003        PMID: 12634479     DOI: 10.1097/00001756-200303030-00008

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  28 in total

1.  Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity.

Authors:  Robert A Bermel; Srinivas R Puli; Richard A Rudick; Bianca Weinstock-Guttman; Elizabeth Fisher; Frederick E Munschauer; Rohit Bakshi
Journal:  Arch Neurol       Date:  2005-09

Review 2.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

Review 3.  Magnetic resonance spectroscopy in the monitoring of multiple sclerosis.

Authors:  Ponnada A Narayana
Journal:  J Neuroimaging       Date:  2005       Impact factor: 2.486

Review 4.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

5.  Gray Matter Changes in Demyelinating Disease: Correlations with Clinical Scores.

Authors:  Mihaela Onu; Adina Aroceanu; Victor Ferastraoaru; Ovidiu Bajenaru
Journal:  Maedica (Bucur)       Date:  2015-09

Review 6.  Magnetic Resonance Imaging in Multiple Sclerosis.

Authors:  Christopher C Hemond; Rohit Bakshi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 7.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 8.  Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.

Authors:  Blandine Grassiot; Béatrice Desgranges; Francis Eustache; Gilles Defer
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

9.  Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis.

Authors:  Antonietta Gentile; Silvia Rossi; Valeria Studer; Caterina Motta; Valentina De Chiara; Alessandra Musella; Helena Sepman; Diego Fresegna; Gabriele Musumeci; Giorgio Grasselli; Nabila Haji; Sagit Weiss; Liat Hayardeny; Georgia Mandolesi; Diego Centonze
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-31       Impact factor: 4.147

10.  Caudate nuclei volume, diffusion tensor metrics, and T(2) relaxation in healthy adults and relapsing-remitting multiple sclerosis patients: implications for understanding gray matter degeneration.

Authors:  Khader M Hasan; Christopher Halphen; Arash Kamali; Flavia M Nelson; Jerry S Wolinsky; Ponnada A Narayana
Journal:  J Magn Reson Imaging       Date:  2009-01       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.